Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Sylvia Lucas

Neurology Seattle, WA Medical Doctor

NPI 1215012026 CMS profile 397571

University Of Washington Medical Ctr, 1959 Ne Pacific St, Seattle, WA 98195

Open in the dashboard

General payments

$90,396

181 records reported · program years 2019–2024

Research payments

$9,759

Paid to them · 2 records reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$8,386 paid to institutions, not to them · program years 2019–2021

Through program year 2024, Sylvia Lucas of Seattle, WA is reported in the CMS Open Payments database as having received $90,396 across 181 general payments and $9,759 in research payments paid to them. Separately, studies naming them as principal investigator received $8,386 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 93rd percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $348 7
2023 General $342 8
2022 General $2,301 7
2021 General $28,495 26
2021 Research $9,530 1
2020 General $39,155 57
2019 General $19,756 76
2019 Research $229 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sylvia Lucas
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Sylvia Lucas were reported at $0. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Sylvia Lucas Neurology median Middle half National median
2019 $19,756 $474 $118–$2,177 $163
2020 $39,155 $367 $82–$2,309 $114
2021 $28,495 $438 $104–$2,547 $132
2022 $2,301 $442 $103–$2,388 $149
2023 $342 $464 $119–$2,312 $160
2024 $348 $468 $119–$2,323 $164
2025 $0 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Lundbeck LLC $30,537 30 payments
  2. Amgen Inc. $16,801 10 payments
  3. Allergan Inc. $16,340 33 payments
  4. Lilly USA, LLC $9,088 51 payments
  5. Biohaven Pharmaceuticals, Inc. $7,532 10 payments
  6. Teva Pharmaceuticals USA, Inc. $6,360 7 payments
  7. Biohaven Pharmaceutical Holding Company Ltd. $2,000 1 payment
  8. EMD Serono, Inc. $938 23 payments
  9. Biogen, Inc. $419 9 payments
  10. Novartis Pharmaceuticals Corporation $221 4 payments
  11. Other $161 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Consulting Fee $39,269 25 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $23,000 12 payments
  3. Honoraria $20,000 6 payments
  4. Food and Beverage $4,563 108 payments
  5. Travel and Lodging $3,441 27 payments
  6. Education $124 3 payments
Products named General payments · program years 2019–2024
  1. VYEPTI $18,235 20 payments
  2. AIMOVIG $16,801 10 payments
  3. UBRELVY Neuroscience $14,342 28 payments
  4. NURTEC ODT $9,532 11 payments
  5. AJOVY Central Nervous System $5,950 1 payment
  6. UBRELVY Neuroscience $1,750 1 payment
  7. EMGALITY $393 7 payments
  8. Ajovy Central Nervous System $369 5 payments
  9. TYSABRI $178 2 payments
  10. Mavenclad $177 6 payments
  11. Other $1,314 25 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2024
  1. Amgen Inc. $9,530 1 payment
  2. Novartis Pharmaceuticals Corporation $229 1 payment

Records

183 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Washington

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record